Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

High-throughput optimisation of light-driven microalgae biotechnologies.

Sivakaminathan S, Hankamer B, Wolf J, Yarnold J.

Sci Rep. 2018 Aug 3;8(1):11687. doi: 10.1038/s41598-018-29954-x.

2.

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.

Wilkins A, Chauhan R, Rust A, Pearson A, Daley F, Manodoro F, Fenwick K, Bliss J, Yarnold J, Somaiah N.

Breast Cancer Res Treat. 2018 Aug;170(3):573-581. doi: 10.1007/s10549-018-4798-7. Epub 2018 Apr 26.

3.

Changes in radiotherapy fractionation-breast cancer.

Yarnold J.

Br J Radiol. 2018 Mar 19:20170849. doi: 10.1259/bjr.20170849. [Epub ahead of print]

PMID:
29345152
4.

Reply to Goodare et al. Re: Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy?

Haviland J, Yarnold J, Bliss J, Hopwood P, Wilcox M.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):665-6. doi: 10.1016/j.clon.2016.07.008. Epub 2016 Jul 28. No abstract available.

PMID:
27477124
5.

Hyperbaric oxygen therapy for chronic bowel dysfunction after pelvic radiotherapy - Authors' reply.

Glover M, Maynard L, Gothard L, Yarnold J; HOT2 Trial Management Group.

Lancet Oncol. 2016 Apr;17(4):e131-e132. doi: 10.1016/S1470-2045(16)00146-7. Epub 2016 Mar 29. No abstract available.

PMID:
27300668
6.

Erratum to "Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy" [Cancer Lett. 374/2 (2016) 324-330].

Nuta O, Somaiah N, Boyle S, Chua ML, Gothard L, Yarnold J, Rothkamm K, Herskind C.

Cancer Lett. 2016 Aug 1;378(1):68. doi: 10.1016/j.canlet.2016.05.009. Epub 2016 May 12. No abstract available.

PMID:
27197782
7.

Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy.

Somaiah N, Chua ML, Bourne S, Daley F, A' Hern R, Nuta O, Gothard L, Boyle S, Herskind C, Pearson A, Warrington J, Helyer S, Owen R, Rothkamm K, Yarnold J.

Radiother Oncol. 2016 May;119(2):244-9. doi: 10.1016/j.radonc.2016.04.012. Epub 2016 Apr 19.

8.

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.

Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, Zotova R, Sydenham M, Griffin CL, Morden JP, Bliss JM; FAST-Forward Trial Management Group.

Radiother Oncol. 2016 Jul;120(1):114-8. doi: 10.1016/j.radonc.2016.02.027. Epub 2016 Apr 1.

9.

Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.

Nuta O, Somaiah N, Boyle S, Chua ML, Gothard L, Yarnold J, Rothkamm K, Herskind C.

Cancer Lett. 2016 May 1;374(2):324-30. doi: 10.1016/j.canlet.2016.02.036. Epub 2016 Mar 2.

PMID:
26944319
10.

ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1.

Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Sola AB, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P.

Radiother Oncol. 2016 Jan;118(1):205-8. doi: 10.1016/j.radonc.2015.12.027. Epub 2016 Jan 18. No abstract available.

PMID:
26791404
11.

Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.

Glover M, Smerdon GR, Andreyev HJ, Benton BE, Bothma P, Firth O, Gothard L, Harrison J, Ignatescu M, Laden G, Martin S, Maynard L, McCann D, Penny CEL, Phillips S, Sharp G, Yarnold J.

Lancet Oncol. 2016 Feb;17(2):224-233. doi: 10.1016/S1470-2045(15)00461-1. Epub 2015 Dec 17.

12.

A multicentre study of the evidence for customized margins in photon breast boost radiotherapy.

Harris EJ, Mukesh MB, Donovan EM, Kirby AM, Haviland JS, Jena R, Yarnold J, Baker A, Dean J, Eagle S, Mayles H, Griffin C, Perry R, Poynter A, Coles CE, Evans PM; IMPORT high trialists.

Br J Radiol. 2016;89(1058):20150603. doi: 10.1259/bjr.20150603. Epub 2015 Nov 20.

13.

Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.

Dorling L, Barnett GC, Michailidou K, Coles CE, Burnet NG, Yarnold J, Elliott RM, Dunning AM, Pharoah PD, West CM.

Clin Cancer Res. 2016 Mar 15;22(6):1413-20. doi: 10.1158/1078-0432.CCR-15-1080. Epub 2015 Oct 28.

14.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS.

Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13. No abstract available.

PMID:
26467471
15.

Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues.

Yarnold J, Somaiah N, Bliss JM.

Breast. 2015 Nov;24 Suppl 2:S108-13. doi: 10.1016/j.breast.2015.07.025. Epub 2015 Aug 3. No abstract available.

PMID:
26249121
16.

In Regard to Vaidya et al.

Yarnold J, Bentzen SM.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):958-959. doi: 10.1016/j.ijrobp.2015.05.033. Epub 2015 Jul 14. No abstract available.

PMID:
26194668
17.

Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?

Somaiah N, Rothkamm K, Yarnold J.

Clin Oncol (R Coll Radiol). 2015 Oct;27(10):570-8. doi: 10.1016/j.clon.2015.06.006. Epub 2015 Jun 21. Review.

PMID:
26108884
18.

XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.

Seibold P, Behrens S, Schmezer P, Helmbold I, Barnett G, Coles C, Yarnold J, Talbot CJ, Imai T, Azria D, Koch CA, Dunning AM, Burnet N, Bliss JM, Symonds RP, Rattay T, Suga T, Kerns SL, Bourgier C, Vallis KA, Sautter-Bihl ML, Claßen J, Debus J, Schnabel T, Rosenstein BS, Wenz F, West CM, Popanda O, Chang-Claude J.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1084-1092. doi: 10.1016/j.ijrobp.2015.04.011. Epub 2015 Apr 11.

PMID:
26072091
19.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS; Definition for the Assessment of Time-to-event Endpoints in Cancer Trials Initiative.

Ann Oncol. 2015 May;26(5):873-9. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Review. Erratum in: Ann Oncol. 2015 Dec;26(12):2505-6.

PMID:
25725046
20.

ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.

Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P.

Radiother Oncol. 2015 Jan;114(1):3-10. doi: 10.1016/j.radonc.2014.11.030. Epub 2015 Jan 24.

PMID:
25630428

Supplemental Content

Loading ...
Support Center